The papulacandins and chaetiacandins constitute a family of glycolipids that have shown potent in vitro antifugual activity against Candida albicans, C. tropicalis, Pneumocystis carinii, and related microorganisms (Chart 1). 1 Opportunistic infections arising from these pathogens are responsible for increased mortality among immunocompromised patients. 2 Papulacandins A-E were isolated and structurally characterized by Traxler The antibiotic and antifungal properties along with the structural complexity of these spiro C-arylated glycopyranosides have stimulated the development of creative solutions for the construction of the tricyclic spiro ketal ring system. Recent representative examples include a synthesis of a racemic-spiro ketal unit via a hetero-DielsAlder 3 reaction and dihydroxylation of 5-aryl-2-vinylfurans followed by Achmatowicz rearrangement. 4 The majority of work has focused on condensation of functionalized organolithium reagents with cyclic or acyclic derivatives of D-gluconolactone. [5] [6] [7] [8] [9] These methods provided rapid access to the spiro ketal core but suffer from moderate to low yields. Alternatively, nucleophilic addition of a lithiated hexenopyranose to a functionalized quinone has been utilized to access the aryl--D-C-glycopyranoside. 10 Finally, Pd-(0)-catalyzed cross-coupling reactions of a protected (tributylstannyl)-hexenopyranose with aryl bromides have been reported. Unfortunately, excess of the toxic tin reagent is required because of dimerization of the donor. 11, 12 Barrett and co-workers reported the first and only total synthesis of any member of the papulacandin family, papulacandin D. 13 Their approach features a condensation of an aryllithium reagent into a protected D-gluconolactone to assemble the spiro ketal moiety. The side-chain carboxylic acid was prepared from L-isoleucine using kinetic resolution to separate the C(7′′) epimers. The two fragments were coupled by acylation using a mixed anhydride of the side chain.
Our synthetic plan for papulacandin D makes the obvious disconnection at the O-C(3) ester linkage to acid 2 and glycopyranoside 1 (Scheme 1). The major challenges in the synthesis resided in these independent units, namely, (1) the construction of the arylglycoside bond and (2) control of the C(7′′) and C(14′′) stereogenic centers. Moreover, potential solutions to these problems could be identified in ongoing methodological studies in these laboratories. First, disconnection of 1 at C(1) reduced the problem to a palladium-catalyzed cross-coupling of glucal silanol 3 and aryl iodide 4. 14 Although we had already reported the synthesis C-aryl-2-H-pyrans from 2-pyranylsilanols, 15 this transformation failed with complex substrates and the fluoride activation was incompatible with silicon protecting groups. Thus, the first challenge was to determine whether the newly developed, fluoride-free variant 16 could be adapted to generate the spirocyclic C-aryl glycopyranoside. Second, inspection of 2 suggested that the C(6′′)-C(7′′) bond could arise from enantioselective addition of allyltrichlorosilane (6) to conjugated aldehyde 5. We have previously described in detail the chiral bisphosphoramide-catalyzed addition of allylic trichlorosilanes into aldehydes. 17 Herein, we report an efficient, enantioselective total synthesis of papulacandin D in which these methods serve as the key strategic steps.
The synthetic plan began with the preparation of aromatic iodide 4. Esterification of commercially available 3,5-dihydroxybenzoic acid to afford methyl ester 8 was followed by protection of the resorcinol hydroxyl groups with benzyl bromide and reduction of the ester with lithium aluminum hydride to afford benzyl alcohol 10 in near quantitative yield (three steps). Finally, iodination of 10 with N-iodosuccinimide provided the aromatic iodide, which was protected as the pivaloyl ester (4) in excellent yield (93%, two steps) (Scheme 2).
The preparation of the spirocyclic C-aryl glycopyranoside began by saponification of triacetate 11 18 to give the free hexenopyranose which was immediately protected as its di(tert-butyl)silylene acetal (Scheme 3). 19 Protection of the C(3)-hydroxyl group with TES-Cl provided fully silyl protected hexenopyranose 12 in 91% yield (two steps). With 12 in hand, the stage was set for implementation of the key cross-coupling reaction. Thus, lithiation and silylation of 12 with chlorodimethylsilane provided 13, which was subjected to oxidative hydrolysis catalyzed by bis[chloro(p-cymene)ruthenium-(II)] 20 in the presence of 2.0 equiv of water to provide silanol 3 in 84% yield. Gratifyingly, the combination of aryl iodide 4 and the silanol 3 proceeded smoothly to afford aryl-hexenopyranose 14 in 82% yield. The vital cross-coupling reaction was carried out with 5 mol % Pd 2 (dba) 3 ‚CHCl 3 as the catalyst and 2.0 equiv of NaOtBu as the activator at 50°C for 5 h. Removal of the pivaloyl group set the stage to elaborate the aryl-hexenopyranose.
The crucial spiro ketalization was effected by treatment of 15 with m-CPBA in the presence of NaHCO 3 to afford a mixture of chromatographically separable anomers 16R (77%) and 16 (15%) (Scheme 4). 21 Initially, protection of the C(2) hydroxyl group was problematic; however, treatment of 16 with a preformed acylpyridinium species followed by addition of 2-(trimethylsilyl)ethanol gave 2-(trimethylsilyl)ethyl carbonate (TEOC)-protected spiro ketal in 92% yield. Debenzylation of 17 with Pd/C proceeded quantitatively. Subsequent TEOC protection of the resorcinol portion was achieved using TEOC-Cl 22 in the presence of 2,6-lutidine to produce the fully silylated spiro ketal 19 in 96% yield overall. Selective removal of the O-C(3) TES group with PPTS/EtOH afforded 20 in 93% yield.
Synthesis of the side-chain unsaturated acid 2 began by asymmetric hydrogenation of geraniol 23 with Ru(OAc) 2 [(S)-BINAP] to provide (S)-citronellol (99%, 97:3 er) (Scheme 5). 24 Tosylation followed by deoxygenation with LiHBEt 3 afforded hydrocarbon 23 in good yield (88%, two steps). Subsequent ozonolysis and Horner-Wadsworth-Emmons 25 olefination afforded unsaturated ester 24, an inseparable mixture of isomers (∆ 10′′,11′′ E/Z, 91:9)). Subsequently, DIBAL-H reduction followed by chromatographic separation of the geometrical isomers and oxidation afforded aldehyde (E,E)-5 in 84% yield (four steps).
The enantioselective allylation of 5 using chiral bisphosphoramide (R,R)-26 17 smoothly provided 27 in good yield and excellent diastereomeric selectivity (88%, dr 96/4). The expected C(7′′) S configuration was confirmed by analysis of Mosher esters. 26 Olefin metathesis with acrolein using Grubbs' second generation catalyst, 27 and protection of the C(7′′) hydroxyl group with TES-Cl gave 29 (91%, two steps). The synthesis of 2 was completed by Wittig olefination and saponification with potassium trimethylsilanoate 28 in excellent yield (90%, two steps).
The coupling of fragments 2 and 20 was achieved via the mixed anhydride of acid 1 from 2,4,6-trichlorobenzoyl chloride 29 and DMAP in good yield (87%) (Scheme 6). Global deprotection proceeded smoothly with HF/Et 3 N (60:40 ratio) in DMSO to afford papulacandin D (89% yield). Synthetic papulacandin D exhibited spectroscopic and physical properties identical to those reported for the natural and synthetic material ( 1 H NMR, 13 C NMR, HRMS, optical rotation, UV-vis). 1, 13 In conclusion, papulacandin D has been synthesized by a convergent synthetic strategy that features a silicon-based, crosscoupling reaction to construct the key spirocyclic C-aryl glycopyranoside 16 and an enantioselective allylation reaction using a chiral bisphosphoramide for the construction of the C(7′′) stereocenter. The application of palladium-catalyzed, silicon-based, crosscoupling reactions in the synthesis of more complex molecules is currently under investigation.
